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Abstract
Problem/Condition: Autism spectrum disorder (ASD) is estimated to affect up to 3% of children in the United States. Public 
health surveillance for ASD among children aged 4 years provides information about trends in prevalence, characteristics of 
children with ASD, and progress made toward decreasing the age of identification of ASD so that evidence-based interventions 
can begin as early as possible.
Period Covered: 2010, 2012, and 2014.
Description of System: The Early Autism and Developmental Disabilities Monitoring (Early ADDM) Network is an active 
surveillance system that provides biennial estimates of the prevalence and characteristics of ASD among children aged 4 years whose 
parents or guardians lived within designated sites. During surveillance years 2010, 2012, or 2014, data were collected in seven sites: 
Arizona, Colorado, Missouri, New Jersey, North Carolina, Utah, and Wisconsin. The Early ADDM Network is a subset of the 
broader ADDM Network (which included 13 total sites over the same period) that has been conducting ASD surveillance among 
children aged 8 years since 2000. Each Early ADDM site covers a smaller geographic area than the broader ADDM Network. Early 
ADDM ASD surveillance is conducted in two phases using the same methods and project staff members as the ADDM Network. 
The first phase consists of reviewing and abstracting data from children’s records, including comprehensive evaluations performed 
by community professionals. Sources for these evaluations include general pediatric health clinics and specialized programs for 
children with developmental disabilities. In addition, special education records (for children aged ≥3 years) were reviewed for 
Arizona, Colorado, New Jersey, North Carolina, and Utah, and early intervention records (for children aged 0 to <3 years) were 
reviewed for New Jersey, North Carolina, Utah, and Wisconsin; in Wisconsin, early intervention records were reviewed for 2014 
only. The second phase involves a review of the abstracted evaluations by trained clinicians using a standardized case definition 
and method. A child is considered to meet the surveillance case definition for ASD if one or more comprehensive evaluations 
of that child completed by a qualified professional describes behaviors consistent with the Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnostic criteria for any of the following conditions: autistic disorder, 
pervasive developmental disorder–not otherwise specified (PDD-NOS, including atypical autism), or Asperger disorder (2010, 
2012, and 2014). For 2014 only, prevalence estimates based on surveillance case definitions according to DSM-IV-TR and the 
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) were compared. This report provides estimates of 
overall ASD prevalence and prevalence by sex and race/ethnicity; characteristics of children aged 4 years with ASD, including age 
at first developmental evaluation, age at ASD diagnosis, and cognitive function; and trends in ASD prevalence and characteristics 
among Early ADDM sites with data for all 3 surveillance years (2010, 2012, and 2014), including comparisons with children 
aged 8 years living in the same geographic area. Analyses of time trends in ASD prevalence are restricted to the three sites that 
contributed data for all 3 surveillance years with consistent data sources (Arizona, Missouri, and New Jersey).
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Results: The overall ASD prevalence was 13.4 per 1,000 children aged 4 years in 2010, 15.3 in 2012, and 17.0 in 2014 for 
Early ADDM sites with data for the specific years. ASD prevalence was determined using a surveillance case definition based on 
DSM-IV-TR. Within each surveillance year, ASD prevalence among children aged 4 years varied across surveillance sites and 
was lowest each year for Missouri (8.5, 8.1, and 9.6 per 1,000, for 2010, 2012, and 2014, respectively) and highest each year for 
New Jersey (19.7, 22.1, and 28.4 per 1,000, for the same years, respectively). Aggregated prevalence estimates were higher for sites 
that reviewed education and health care records than for sites that reviewed only health care records. Among all participating sites 
and years, ASD prevalence among children aged 4 years was consistently higher among boys than girls; prevalence ratios ranged 
from 2.6 (Arizona and Wisconsin in 2010) to 5.2 boys per one girl (Colorado in 2014). In 2010, ASD prevalence was higher 
among non-Hispanic white children than among Hispanic children in Arizona and non-Hispanic black children in Missouri; no 
other differences were observed by race/ethnicity. Among four sites with ≥60% data on cognitive test scores (Arizona, New Jersey, 
North Carolina, and Utah), the frequency of co-occurring intellectual disabilities was significantly higher among children aged 
4 years than among those aged 8 years for each site in each surveillance year except Arizona in 2010. The percentage of children 
with ASD who had a first evaluation by age 36 months ranged from 48.8% in Missouri in 2012 to 88.9% in Wisconsin in 
2014. The percentage of children with a previous ASD diagnosis from a community provider varied by site, ranging from 43.0% 
for Arizona in 2012 to 86.5% for Missouri in 2012. The median age at earliest known ASD diagnosis varied from 28 months 
in North Carolina in 2014 to 39.0 months in Missouri and Wisconsin in 2012. In 2014, the ASD prevalence based on the 
DSM-IV-TR case definition was 20% higher than the prevalence based on the DSM-5 (17.0 versus 14.1 per 1,000, respectively).
Trends in ASD prevalence and characteristics among children aged 4 years during the study period were assessed for the three sites 
with data for all 3 years and consistent data sources (Arizona, Missouri, and New Jersey) using the DSM-IV-TR case definition; 
prevalence was higher in 2014 than in 2010 among children aged 4 years in New Jersey and was stable in Arizona and Missouri. 
In Missouri, ASD prevalence was higher among children aged 8 years than among children aged 4 years. The percentage of 
children with ASD who had a comprehensive evaluation by age 36 months was stable in Arizona and Missouri and decreased in 
New Jersey. In the three sites, no change occurred in the age at earliest known ASD diagnosis during 2010–2014.
Interpretation: The findings suggest that ASD prevalence among children aged 4 years was higher in 2014 than in 2010 in one site 
and remained stable in others. Among children with ASD, the frequency of cognitive impairment was higher among children aged 
4 years than among those aged 8 years and suggests that surveillance at age 4 years might more often include children with more severe 
symptoms or those with co-occurring conditions such as intellectual disability. In the sites with data for all years and consistent data 
sources, no change in the age at earliest known ASD diagnosis was found, and children received their first developmental evaluation 
at the same or a later age in 2014 compared with 2010. Delays in the initiation of a first developmental evaluation might adversely 
affect children by delaying access to treatment and special services that can improve outcomes for children with ASD.
Public Health Action: Efforts to increase awareness of ASD and improve the identification of ASD by community providers can 
facilitate early diagnosis of children with ASD. Heterogeneity of results across sites suggests that community-level differences in 
evaluation and diagnostic services as well as access to data sources might affect estimates of ASD prevalence and age of identification. 
Continuing improvements in providing developmental evaluations to children as soon as developmental concerns are identified 
might result in earlier ASD diagnoses and earlier receipt of services, which might improve developmental outcomes.
Introduction
Autism spectrum disorder (ASD) is a developmental 
disability marked by social and communication impairments, 
as well as restricted interests and repetitive behaviors (1). ASD 
prevalence has been measured by special education and other 
administrative records (2–4), national surveys (5–9), and active 
public health surveillance conducted through the Metropolitan 
Atlanta Developmental Disabilities Surveillance Program 
(MADDSP) and its extended surveillance network, the 
Autism and Developmental Disabilities Monitoring (ADDM) 
Network (10–17). ASD prevalence was first measured by CDC 
among children aged 3–10 years children by MADDSP in 
1996 (16). In that analysis, the peak prevalence of ASD was 
determined to be at age 8 years. Therefore, subsequent to that 
report, CDC has reported ASD prevalence among children 
aged 8 years based on data collected every 2 years from 2000 
through 2014. Surveillance was conducted by MADDSP and 
other sites across the United States that participated in the 
ADDM Network. The most recent ASD prevalence estimate 
from the ADDM Network was 16.8 per 1,000 children aged 
8 years in 2014 (13), compared with 14.5 per 1,000 in 2012 
(14) and 14.7 per 1,000 in 2010 (15).
Measuring ASD prevalence and age at diagnosis in elementary 
school–aged children is expected to yield the most complete 
information on ASD prevalence and characteristics (13–15); 
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however, measuring ASD prevalence in preschool-aged children 
provides more timely assessment of efforts to increase awareness 
and early detection of ASD. Evidence linking early treatment 
for ASD with improved outcomes (18–21) implies that an 
absence or delay in ASD identification could adversely affect 
children by delaying interventions and initiation of special 
services. The American Academy of Pediatrics supports early 
identification in their recommendation that all children receive 
ASD screening at ages 18 and 24 months (22). Each state has 
programs to identify children with disabilities and provide 
special services from birth through age 2 years; children at 
risk for or with disabilities are eligible for early intervention 
services through part C of the Individuals with Disabilities 
Education Act (IDEA) (http://idea.ed.gov). Children aged 
≥3 years with disabilities are eligible for evaluation and special 
education services through part B of IDEA, and these services 
are provided by public school systems (http://idea.ed.gov).
This report describes ASD prevalence estimates and 
characteristics among children aged 4 years in the Early 
ADDM Network for 2010, 2012, and 2014. Selected trend 
analyses also are presented. The findings in this report can 
be used by pediatric health care providers, early intervention 
service providers, therapists, school psychologists, educators, 
researchers, policymakers, and program administrators seeking 
to understand and provide for the needs of persons with ASD 
and their families. These data can be used to help plan for 
service needs and initiate and implement policies that promote 
early identification of children with ASD.
Methods
To estimate the prevalence of ASD in a younger age group, 
seven of the 13 ADDM sites that conducted ASD surveillance 
among children aged 8 years during 2010, 2012, 2014 (or all 
these years) also collected ASD surveillance data for children 
aged 4 years. These sites are collectively known as the Early 
ADDM Network. The data for children aged 4 years were 
collected in subsets of the ADDM geographic areas for children 
aged 8 years. 
Study Sites
The ADDM Network uses a multisite, multiple-source, 
records-based surveillance method based on a model developed 
by CDC’s MADDSP (16,23). In 2010, 2012, and 2014, a total 
of 13 sites contributed data to the ADDM Network of ASD 
surveillance among children aged 8 years for at least 1 year 
(Alabama, Arizona, Arkansas, Colorado, Georgia, Maryland, 
Minnesota, Missouri, New Jersey, North Carolina, Tennessee, 
Utah, and Wisconsin). As part of the Early ADDM Network, 
seven of these sites also conducted ASD surveillance and 
reported data for children aged 4 years for at least 1 year. The 
Early ADDM Network included areas of Arizona, Colorado, 
Missouri, New Jersey, North Carolina, Utah, and Wisconsin 
(Figure 1). Five Early ADDM sites participated in 2010 and 
2012, and six sites participated in 2014. Three Early ADDM 
sites (Arizona, Missouri, and New Jersey) contributed data and 
had consistent data sources in all 3 surveillance years.
Because of resource constraints, Early ADDM surveillance 
was not conducted for the total geographic area covered by 
each study site’s ADDM surveillance for children aged 8 years; 
rather, each Early ADDM Network surveillance area was a 
subset of the site’s total ADDM surveillance area. Each Early 
ADDM surveillance area included at least 8,000 children 
aged 4 years and a similar number of children aged 8 years. In 
comparison, the total ADDM surveillance areas for children 
aged 8 years for each site included 9,767–51,161 children. The 
Early ADDM surveillance areas were not random subsets of the 
total surveillance areas for the respective sites but were selected 
to form areas of full counties or school districts, within the total 
ADDM surveillance area that met or exceeded the minimum 
population size of 8,000 children aged 4 years. Therefore, 
prevalence estimates for children aged 4 years generated by 
the Early ADDM Network should not be interpreted as being 
representative of the prevalence among children aged 4 years 
for the total ADDM study area at a given site.
Children included in this analysis were born in 2006, 2008, 
or 2010 for the surveillance years 2010, 2012, and 2014, 
respectively, and had a parent or guardian who lived in the Early 
ADDM Network surveillance area during all or part of the 
specific surveillance year. Participating Early ADDM sites were 
selected through a competitive review process and were not 
selected to be nationally representative. A diverse population 
was preferred during the review process. Each ADDM site 
functioned as a public health authority under HIPAA (the 
Health Insurance Portability and Accountability Act of 1996) 
and met applicable local Institutional Review Board, privacy, 
and confidentiality requirements (24).
Case Ascertainment
ADDM is an active surveillance system that does not 
depend on family or professional reporting of an existing ASD 
diagnosis or classification to determine ASD case status. Case 
determination is a two-phase process. The first phase involves 
review and abstraction of records at multiple data sources in 
the community. In the second phase, all abstracted evaluations 
are compiled and reviewed by trained study personnel to 
determine ASD case status. Data sources are categorized as 
either 1) education source type, including evaluations to 
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FIGURE 1. Early Autism and Developmental Disabilities Monitoring Network surveillance areas — seven sites, United States, 2010, 2012, and 2014
determine eligibility for special education services or 2) health 
care source type, including diagnostic and developmental 
evaluations. Evaluations must have been performed by a 
qualified professional, such as a psychologist, physician, 
physical therapist, occupational therapist, speech or language 
pathologist, or educator. Children’s records are screened from 
multiple data sources to determine eligibility for inclusion as a 
potential case. Developmental assessments completed by a wide 
range of health care and education providers are reviewed. All 
Early ADDM Network sites had agreements in place to access 
records at health care sources. Special education records (for 
children aged ≥3 years) were reviewed in Arizona, Colorado, 
New Jersey, North Carolina, and Utah, and early intervention 
records (for children aged 0 to <3 years) were reviewed in New 
Jersey, North Carolina, Utah, and Wisconsin; in Wisconsin, 
early intervention records were reviewed for 2014 only. The 
ADDM Network review only includes existing records, not 
clinical examinations of children.
In the first phase of surveillance, ADDM Network sites 
identify source records to review according to a child’s year of 
birth and either 1) eligibility classifications in special education 
or early intervention, or 2) International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
or International Classification of Diseases, Tenth Revision 
(ICD-10) billing codes for select childhood disabilities or 
conditions. Children’s records are screened to confirm year 
of birth and residency in the surveillance area at some time 
during the surveillance year. For children meeting age and 
residency requirements, the source files are screened for certain 
behavioral or diagnostic descriptions defined by ADDM as 
triggers for abstraction (e.g., child does not initiate interactions 
with others, prefers to play alone or engage in solitary 
activities, or has received a documented ASD diagnosis). If 
abstraction triggers are found, evaluation information from 
birth through the current surveillance year is abstracted into a 
single composite record for each child. The composite record 
includes comprehensive evaluations by qualified professionals 
from birth through the end of the year when the child reaches 
either age 4 or 8 years.
In the second phase of surveillance, the abstracted 
comprehensive evaluations are deidentified and reviewed 
systematically by clinicians who have undergone standardized 
training to determine ASD case status using a coding scheme 
based on the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition, Text Revision (DSM-IV-TR) (25) 
criteria for ASD. These clinicians review each comprehensive 
evaluation and code the behavioral descriptors according to 
the DSM-IV-TR criteria represented by the descriptor. 
Surveillance Summaries
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Surveillance Case Definition
Children included in this analysis were born in 2006, 2008, or 
2010 for the surveillance years 2010, 2012, and 2014, respectively, 
and had a parent or guardian who lived in the Early ADDM 
Network surveillance area during all or part of the specific 
surveillance year. A child aged 4 or 8 years met the surveillance 
case definition for ASD if behaviors described within one or more 
comprehensive evaluations were consistent with the DSM-IV-TR 
diagnostic criteria for any of the following conditions: autistic 
disorder, pervasive developmental disorder–not otherwise specified 
(PDD-NOS, including atypical autism), or Asperger disorder 
(Box 1). An ASD diagnosis alone was not sufficient to meet the 
DSM-IV-TR surveillance case definition but was considered 
during the clinician review process, along with behavioral 
criteria. Most records were reviewed by a single person, 
although clinicians were able to request a second review if they 
were uncertain about whether the behaviors were consistent 
with the DSM-IV-TR diagnostic criteria. Children could have 
been disqualified from meeting the case definition if their 
behaviors met the surveillance case definition but one or more 
clinician reviewers judged that sufficient information existed to 
rule out ASD, information to support an ASD diagnosis was 
conflicting or insufficient, or that one or more other diagnosed 
conditions better accounted for their symptoms.
Updated behavioral criteria for an ASD diagnosis were 
published in 2013 in the Diagnostic and Statistical Manual 
of Mental Disorders, 5th Edition (DSM-5) (1). To determine 
the effect of the updated DSM-5 behavioral criteria on ASD 
prevalence, a revised surveillance case definition (Box 2) also 
was used to classify cases for the 2014 surveillance year. A child 
aged 4 or 8 years met the DSM-5 surveillance case definition if 
behaviors described within one or more comprehensive evaluations 
were consistent with the DSM-5 diagnostic criteria or if an 
ASD diagnosis had been documented, regardless of whether the 
behavioral criteria had been met. Most records were reviewed by 
a single person, although clinicians were able to request a second 
review if they were uncertain about whether the behaviors were 
consistent with the DSM-5 diagnostic criteria. Children could 
have been disqualified from meeting the case definition if their 
behaviors met the surveillance case definition but one or more 
clinician reviewers judged that sufficient information existed to 
rule out ASD, information to support an ASD diagnosis was 
conflicting or insufficient, or that one or more other diagnosed 
conditions better accounted for their symptoms.
In this report, most results are based on the DSM-IV-TR 
surveillance case definition for consistency and comparison 
across surveillance years. Results comparing ASD prevalence 
using both DSM-IV-TR and DSM-5 surveillance case 
definitions are included for 2014.
Descriptive Characteristics
Demographic information, including sex and race/ethnicity, 
was abstracted. Data on sex were available for all children. 
Data on race/ethnicity were missing for <5% of children 
across all years, age groups, and surveillance sites. Children 
with missing race/ethnicity data were not included in analyses 
stratified by race/ethnicity but were included in analyses of all 
children combined. Each site obtained vital records data for the 
relevant birth year, which were linked to surveillance data to 
obtain supplemental information on race/ethnicity and other 
demographic characteristics.
Diagnostic summaries from each evaluation were abstracted 
for each child, including notation of any ASD diagnosis by 
subtype. Children were considered to have an ASD diagnosis 
from a community provider if they received a diagnosis of 
autistic disorder, Asperger disorder, PDD-NOS, or ASD that 
was documented in an abstracted evaluation at any time from 
birth through the year when they reached age 4 or 8 years. The 
age at each documented ASD diagnosis from a community 
provider was abstracted, as well as the age at each comprehensive 
developmental evaluation. These data were used to determine 
the age at the earliest known ASD diagnosis, if any, and the 
age at the first comprehensive developmental evaluation. Data 
on age at first evaluation were restricted to children who were 
born in the state where the ADDM Network site was located 
to avoid bias from the inability to locate early evaluations for 
children who moved into the study area. In-state birth was 
determined through a successful match to a birth certificate 
from that state. If no birth certificate was found, the child 
was presumed to have been born outside the state where the 
surveillance site was located. Because all children had at least 
one evaluation, the age at the first evaluation was available for 
all children and is reported as the median age (in months), 
along with the percentage of children with a first evaluation by 
age 36 months. This age was chosen to align with the Healthy 
People 2020 (http://www.healthypeople.gov/2020/default.
aspx) goal of increasing the percentage of children with ASD 
who receive their first developmental evaluation by the age of 
36 months. Not all children had a documented ASD diagnosis 
from a community provider; a total of 272 (34.7%), 318 
(35.1%), and 508 (42.1%) children had no ASD diagnosis for 
2010, 2012, and 2014, respectively. The age at earliest known 
ASD diagnosis could be described only for those children with 
a documented diagnosis and is reported as the median age in 
months. Ages of <6 months at earliest known ASD diagnosis 
were excluded for implausibility (n = 2). 
Data were collected on results of standardized tests of 
intellectual ability found in children’s records, and children 
were considered to have an intellectual disability if they had 
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BOX 1. Surveillance case definition based on behavioral criteria for diagnosis of autism spectrum disorder: Diagnostic and Statistical Manual 
of Mental Disorders, 4th Edition, Text Revision
DSM-IV-TR behavioral criteria
Social 1a. Marked impairment in the use of multiple nonverbal behaviors, such as eye-to-eye gaze, facial expression, body postures, 
and gestures to regulate social interaction
1b. Failure to develop peer relationships appropriate to developmental level
1c. A lack of spontaneous seeking to share enjoyment, interests, or achievements with other people (e.g., by a lack of showing, 
bringing, or pointing out objects of interest)
1d. Lack of social or emotional reciprocity 
Communication 2a. Delay in, or total lack of, the development of spoken language (not accompanied by an attempt to compensate through 
alternative modes of communication, such as gesture or mime)
2b. In individuals with adequate speech, marked impairment in the ability to initiate or sustain a conversation with others
2c. Stereotyped and repetitive use of language or idiosyncratic language
2d. Lack of varied, spontaneous make-believe play or social imitative play appropriate to developmental level 
Restricted behavior/Interest 3a. Encompassing preoccupation with one or more stereotyped and restricted patterns of interest that is abnormal either in 
intensity or focus
3b. Apparently inflexible adherence to specific, nonfunctional routines, or rituals
3c. Stereotyped and repetitive motor mannerisms (e.g., hand or finger flapping or twisting, or complex whole body movements)
3d. Persistent preoccupation with parts of objects
Developmental history Child had identified delays or any concern with development in the following areas at or before the age of 3 years: 
Social, Communication, Behavior, Play, Motor, Attention, Adaptive, or Cognitive
Autism discriminators Oblivious to children
Oblivious to adults or others
Rarely responds to familiar social approach
Language primarily echolalia or jargon
Regression/loss of social, language, or play skills
Previous ASD diagnosis, whether based on DSM-IV-TR or DSM-5 diagnostic criteria
Lack of showing, bringing, etc.
Little or no interest in others
Uses others as tools
Repeats extensive dialog
Absent or impaired imaginative play
Markedly restricted interests
Unusual preoccupation
Insists on sameness
Nonfunctional routines
Excessive focus on parts
Visual inspection
Movement preoccupation
Sensory preoccupation
DSM-IV-TR surveillance case definition
At least six behaviors coded with a minimum of two Social, one Communication, and one Restricted Behavior/Interest; AND evidence of developmental delay 
or concern at or before the age of 3 years
OR
At least two behaviors coded with a minimum of one Social and either one Communication and/or one Restricted Behavior/Interest; AND at least one autism 
discriminator coded
Note: A child might be disqualified from meeting the DSM-IV-TR surveillance case definition for ASD if, based on the clinical judgment of one or more reviewers, 
there is insufficient or conflicting information in support of ASD, sufficient information to rule out ASD, or if one or more other diagnosed conditions better 
account for the child’s symptoms. 
Abbreviations: ASD = autism spectrum disorder; DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; DSM-5= Diagnostic 
and Statistical Manual of Mental Disorders, Fifth Edition.
a score of ≤70 on their most recent test. Data on intellectual 
ability were included for sites for which ≥60% of children 
meeting the ASD surveillance case definition had an intellectual 
ability test score. Among those sites, children without a test 
score were categorized as having unknown intellectual ability 
(n = 114 [18.8%], n = 114 [21.5%], and n = 225 [25.7%] for 
2010, 2012, and 2014, respectively). Uncertainty surrounding 
the reliability of measurement of intellectual ability in early 
childhood prevents further subclassification of intellectual 
ability (26,27).
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MMWR / April 12, 2019 / Vol. 68 / No. 2 7US Department of Health and Human Services/Centers for Disease Control and Prevention
BOX 2. Surveillance case definition based on behavioral criteria for diagnosis of autism spectrum disorder*: Diagnostic and Statistical Manual 
of Mental Disorders, 5th Edition
DSM-5 behavioral criteria
A. Persistent deficits in social 
communication and social 
interaction
A1: Deficits in social emotional reciprocity
A2. Deficits in nonverbal communicative behaviors
A3. Deficits in developing, maintaining, and understanding relationships
B. Restricted, repetitive patterns 
of behavior, interests, or 
activities, currently or by 
history
B1: Stereotyped or repetitive motor movements, use of objects or speech
B2. Insistence on sameness, inflexible adherence to routines, or ritualized patterns of verbal or nonverbal behavior
B3. Highly restricted interests that are abnormal in intensity or focus
B4. Hyperreactivity or hyporeactivity to sensory input or unusual interest in sensory aspects of the environment
Historical pervasive developmental 
disorder diagnosis
Any ASD diagnosis documented in a comprehensive evaluation, including a DSM-IV diagnosis of autistic disorder, Asperger 
disorder, or pervasive developmental disorder–not otherwise specified
DSM-5 surveillance case definition
All three behavioral criteria coded under part A, and at least two behavioral criteria coded under part B
OR
Any ASD diagnosis documented in a comprehensive evaluation, whether based on DSM-IV-TR or DSM-5 diagnostic criteria
Note: A child might be disqualified from meeting the DSM-5 surveillance case definition for ASD if, based on the clinical judgment of one or more reviewers, 
there is insufficient or conflicting information in support of ASD, sufficient information to rule out ASD, or if one or more other diagnosed conditions better 
account for the child’s symptoms.
Abbreviations: ASD = autism spectrum disorder; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; DSM-IV-TR = Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; DSM-V = Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
* DSM-5 also includes a previous DSM-IV diagnosis of ASD as a sole criterion for a clinical diagnosis. 
Quality Assurance
All Early ADDM sites follow the same quality assurance 
conventions established by the ADDM Network. For the 
first phase of ADDM, screening and abstraction of source 
records are checked periodically for accuracy. For the second 
phase, interrater reliability receives ongoing monitoring, with 
a blinded, random 10% sample of abstracted records that are 
scored independently by two reviewers. Across surveillance 
years, the final average interrater agreements for determining 
ASD surveillance case status in the Early ADDM study sites 
ranged from 87.3% (κ = 0.74) to 91.1% (κ = 0.81) among 
children aged 4 years and from 89.2% (κ = 0.77) to 91.0% 
(κ = 0.80) among those aged 8 years.
Analytic Methods
The objectives of this report are to describe ASD prevalence 
and characteristics among children aged 4 years in the Early 
ADDM Network for 2010, 2012, and 2014, including 
1) overall prevalence and prevalence by sex and race/ethnicity; 
2) characteristics of children aged 4 years with ASD, including 
age at first developmental evaluation, age at ASD diagnosis, 
and cognitive function; and 3) trends in ASD prevalence 
and characteristics in the three Early ADDM sites with data 
and consistent data sources for all 3 surveillance years (2010, 
2012, and 2014), including comparisons with children aged 
8 years living in the same geographic areas. Data for 2010 
were previously published (28) but are included in the results 
to provide a comprehensive representation of ASD prevalence 
and characteristics for all the years of Early ADDM Network 
surveillance, as well as a comparison among children from the 
sites with data from all 3 surveillance years.
The prevalence estimate of ASD among children aged 
4 years was calculated as the number of children aged 4 years 
who met the ASD surveillance case definition in the Early 
ADDM Network sites in 2010, 2012, and 2014 divided by 
the number of children aged 4 years living in the surveillance 
areas according to the 2010 decennial bridged-race population 
estimates (29), the vintage 2014 postcensal bridged-race 
population estimates for 2012 (http://www.cdc.gov/nchs), and 
the vintage 2016 postcensal bridged-race population estimates 
for 2014 (http://www.cdc.gov/nchs). In Arizona and Utah, 
the surveillance area included some but not all of the school 
districts in two counties (Maricopa and Salt Lake counties, 
respectively). Therefore, investigators developed a method 
using census and school district data to estimate the numbers 
of children aged 4 and 8 years living in these surveillance areas. 
Detailed methods are provided (Appendix). Overall prevalence 
estimates included all children identified with ASD regardless 
of sex, race/ethnicity, or intellectual ability and therefore were 
unaffected by the availability of these data elements.
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Statistical tests and 95% confidence interval (CI) estimates 
were derived under the assumption that the observed counts 
of ASD surveillance cases were sampled from an underlying 
Poisson distribution. Because previous ADDM Network 
reports presented CIs based on an underlying Poisson 
distribution with an asymptotic approximation to the 
normal, slight differences might exist between those and the 
exact Poisson confidence intervals presented in this report. 
Generalized linear models with a Poisson distribution were 
used to calculate prevalence ratios (PRs) and CIs. Pearson 
chi-square tests were used to examine frequency differences in 
the characteristics of children with ASD by surveillance area, 
sex, race/ethnicity, and intellectual ability; ASD prevalence 
was estimated both for children aged 4 years and 8 years 
living in the Early ADDM surveillance areas. Because the 
data for children aged 8 years are restricted to this smaller 
area, the estimates for those aged 8 years do not match those 
previously published from the ADDM Network reports on 
ASD prevalence and characteristics (13–15). Trend analyses 
for ASD prevalence were restricted to the three sites (Arizona, 
Missouri, and New Jersey) with data and consistent data 
sources for all 3 years; trends in the proportion of children 
with ASD who had co-occurring intellectual disabilities were 
restricted to the two sites with data for all 3 years (Arizona 
and New Jersey). Cochran-Armitage trend tests were used to 
estimate the significance of changes in ASD characteristics 
over the 2010–2014 period. The nonparametric median 
test was used to determine differences in median age at first 
developmental evaluation and earliest known ASD diagnosis 
from 2010 to 2014 and by sex and race/ethnicity within 
surveillance years. PRs with CIs that did not include 1.00 
were used to assess whether ASD prevalence was higher in 
one population than another. For results from chi-square, 
Cochran-Armitage, and median tests, a p value of <0.05 was 
considered significant. Analyses were performed using SAS 
(version 9.4; SAS Institute).
Results
Population Distribution
The overall Early ADDM Network geographic surveillance 
area includes the seven sites that participated in at least one 
surveillance year (Figure 1). The Early ADDM Network 
comprised a population from 58,467 (2010) to 70,887 (2014) 
children aged 4 years and 56,727 (2010) to 71,928 (2014) 
children aged 8 years (Supplemental Table 1, https://stacks.
cdc.gov/view/cdc/76016). The distribution of children by 
race/ethnicity varied across the sites. Among children aged 
4 years, the percentage of white children ranged from 29.4% 
(New Jersey in 2014) to 70.9% (Wisconsin in 2014), and 
the percentage of black children ranged from 3.5% (Arizona 
in 2012 and 2014) to 33.1% (New Jersey in 2014). The 
percentage of Hispanic children ranged from 4.5% (Missouri 
in 2014) to 47.3% (Colorado in 2014). American Indian/
Alaska Native children comprised 0.2%–3.1% of the total 
population, and Asian/Pacific Islander children comprised 
2.7%–6.5%. The population distribution by race/ethnicity 
across sites was similar for children aged 8 years. Aggregating 
data across sites for each surveillance year, the total percentages 
by race/ethnicity among children aged 4 years ranged from 
46.8% to 51.9% for white (in 2014 and 2010, respectively), 
19.1% to 22.7% for black (in 2010 and 2014, respectively), 
23.2% to 25.1% for Hispanic (in 2010 and 2014, respectively), 
4.7% to 5.0% for Asian/Pacific Islander (in 2014 and 2012, 
respectively), and 0.7% to 0.9% for American Indian/Alaska 
Native (in 2014 and 2010–2012, respectively), with similar 
percentages among children aged 8 years.
Overall ASD Prevalence 
Among Children Aged 4 Years
Aggregating data across participating surveillance sites for 
each year, the estimated prevalence of ASD among children 
aged 4 years was 13.4 per 1,000 in 2010, 15.3 in 2012, and 
17.0 in 2014 (Table 1). Prevalence ranged from 8.1 per 1,000 
children aged 4 years in Missouri (2012) to 28.4 in New Jersey 
(2014). For each year, aggregated ASD prevalence was higher 
for study sites that reviewed education and health care records 
rather than health care records alone (Table 1); PRs for sites that 
reviewed both types compared with only health care records 
were 1.8 (95% CI: 1.6–2.2) in 2010, 1.6 (95% CI: 1.4–1.8) 
in 2012, and 1.7 (95% CI: 1.5–2.0) in 2014 (data not shown).
ASD Prevalence 
Among Children Aged 4 Years 
by Sex and Race/Ethnicity
Across all sites and years, ASD prevalence per 1,000 boys 
aged 4 years ranged from 12.2 in Missouri (2010) to 44.0 
in New Jersey (2014) (Table 2). Prevalence per 1,000 girls 
aged 4 years ranged from 3.2 in Missouri (2012) to 12.1 
in New Jersey (2014). Male-to-female PRs indicated ASD 
prevalence was higher among boys than girls in all sites and 
years, ranging from 2.6 (Arizona and Wisconsin in 2010) to 
5.2 boys per one girl (Colorado in 2014).
Across all study sites and years for children aged 4 years, 
prevalence among white children ranged from 7.7 per 1,000 
in Missouri (2014) to 29.3 in New Jersey (2014) (Table 3). 
Prevalence among black children ranged from 3.8 per 1,000 
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in Missouri (2010) to 24.7 in New Jersey (2014). Prevalence 
among Hispanic children ranged from 9.1 per 1,000 (in 
Arizona (2010) to 28.2 in New Jersey (2014). In 2010, white 
children had a higher ASD prevalence than Hispanic children in 
Arizona (PR = 1.7) and black children in Missouri (PR = 2.5); 
no other differences were observed by race/ethnicity.
Frequency of Co-Occurring 
Intellectual Disabilities 
Among Children Aged 4 and 8 Years
Scores on intellectual ability tests were available for at least 
60% of children in four sites for at least one surveillance year 
(Arizona, New Jersey, North Carolina, and Utah). These sites 
all reviewed education and health care records. In the two 
sites (Arizona and New Jersey) with data for all surveillance 
years, the percentage of children aged 4 years with ASD who 
had co-occurring intellectual disabilities was stable over time 
at 47.0%, 43.6%, and 46.0% in 2010, 2012, and 2014, 
respectively (test for trend p value = 0.84) and also was stable 
over time among both boys and girls (Table 4). The proportion 
of children with ASD who had co-occurring intellectual 
disabilities was significantly higher among children aged 4 years 
than among those aged 8 years across all sites and surveillance 
years, with the exception of Arizona (2010) (Supplemental 
Table 2, https://stacks.cdc.gov/view/cdc/76016).
Age at First Comprehensive 
Developmental Evaluation 
Among Children Aged 4 Years
Across all participating sites and surveillance years and 
among children born in the state where the ADDM Network 
site was located, the percentage of children who received 
their first comprehensive developmental evaluation by age 
36 months ranged from 48.8% (Missouri in 2012) to 88.9% 
(Wisconsin in 2014) (Table 5). Among the three sites with 
data and consistent data sources for all 3 years, patterns in the 
age at the first developmental evaluation varied by site. No 
trend was observed in Arizona or Missouri. In New Jersey, 
from 2010 to 2014, the percentage of children who received a 
first evaluation by age 36 months decreased significantly (from 
76.5% to 66.7%). In Wisconsin, the percentage of children 
who received a first developmental evaluation by age 36 months 
was higher in 2014 (88.9%), when early intervention records 
were reviewed, than in 2010 and 2012 (69.0% and 73.4%, 
respectively). Percentages stratified by sex and race/ethnicity 
by site are provided (Supplemental Table 3, https://stacks.cdc.
gov/view/cdc/76016).
ASD Diagnosis from a Community 
Provider Among Children Aged 4 Years
The percentage of children with a documented ASD 
diagnosis from a community provider ranged from 43.0% 
in Arizona (2012) to 86.5% in Missouri (2012) but did not 
vary by sex (Table 6). The median age at first known ASD 
diagnosis ranged from 28 months in North Carolina (2014) 
to 39.0 months in Missouri and Wisconsin (2012). Among the 
three sites with data for all 3 surveillance years and consistent 
data sources, no significant trends were found in the proportion 
of children with an ASD diagnosis, overall or by sex
Trends in ASD Prevalence 
Among Children Aged 4 and 8 Years
Four Early ADDM Network sites (Arizona, Missouri, New 
Jersey, and Wisconsin) participated in all 3 surveillance years; 
however, Wisconsin reviewed early intervention records in 
2014 but not earlier years, whereas data sources for other 
sites were consistent across years. Among children aged 
4 years, ASD prevalence was higher in 2014 than in 2010 in 
New Jersey (PR: 1.4) but not in Arizona or Missouri (Figure 2; 
Supplemental Table 4, https://stacks.cdc.gov/view/cdc/76016). 
In Wisconsin, ASD prevalence was higher in 2012 and 2014 
than in 2010. Among children aged 8 years living in the Early 
ADDM Network geographical areas, ASD prevalence was 
higher in 2014 than in 2010 in New Jersey (PR: 1.3) but not 
in the other sites.
In Missouri and Wisconsin, ASD prevalence was higher 
among children aged 8 years than among those aged 4 years in 
all 3 years (Supplemental Table 4, https://stacks.cdc.gov/view/
cdc/76016). In Arizona, ASD prevalence was higher among 
children aged 8 years than among those aged 4 years in 2012 
only, and in New Jersey, no differences by age were found.
ASD Prevalence Using DSM-IV-TR and 
DSM-5 Case Definitions
A revised ADDM Network ASD surveillance case definition 
was developed for the 2014 surveillance year to provide ASD 
prevalence estimates based on the updated DSM-5 diagnostic 
criteria published in 2013. All sites reviewed children’s 
records in the Early ADDM Network by both surveillance 
case definitions to evaluate the effect on estimated prevalence 
because of the change to DSM-5 diagnostic criteria. Among 
children aged 4 years in the Early ADDM Network in 2014, 
the prevalence of ASD using the DSM-5 surveillance case 
definition was 14.1 compared with 17.0 for DSM-IV-TR 
(DSM-IV-TR-to-DSM-5  PR:  1.2) (Table 7). Among 
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1,237 children who met the surveillance case definition for 
either DSM-IV-TR or DSM-5, 974 (78.7%) met both case 
definitions, 234 (18.9%) met the DSM-IV-TR but not the 
DSM-5 case definition, and 29 (2.3%) met the DSM-5 but 
not the DSM-IV-TR case definition.
Discussion
This report provides data on ASD prevalence among children 
aged 4 years using ADDM surveillance methods across several 
sites participating in the Early ADDM Network during 2010, 
2012, and 2014. Among these children aged 4 years, overall 
estimated ASD prevalence was 13.4 per 1,000 in 2010, 15.3 in 
2012, and 17.0 in 2014. ASD prevalence was higher among boys 
than girls. Across all sites and surveillance years, few differences 
in ASD prevalence were found by race/ethnicity among children 
aged 4 years, and those that were identified occurred in 2010 
but not in later years. In the four sites that participated in Early 
ADDM Network surveillance in all 3 years, ASD prevalence 
among children aged 4 years was approximately 40% higher 
in New Jersey in 2014 than in 2010 and similar across the 
years in Arizona and Missouri. In Wisconsin, ASD prevalence 
was significantly higher in 2014 than in 2010. However, the 
availability of early intervention records in 2014 but not in 
earlier years might have influenced the prevalence estimates for 
that year, even though prevalence was similar in 2012 when early 
intervention records were not reviewed.
The overall prevalence estimate using a DSM-IV-TR case 
definition was approximately 20% higher than the prevalence 
estimate based on DSM-5 criteria. Meeting the DSM-5 
surveillance case definition required either documentation of 
the more extensive behavioral criteria required for a DSM-5 
diagnosis or an ASD diagnosis by a community provider, and 
preschool-aged children might have had fewer comprehensive 
evaluations containing behavioral information and been less 
likely to have a diagnosis. For the 2016 surveillance year, all 
ADDM Network surveillance sites will use the DSM-5 case 
definition, and trends in the prevalence of ASD among children 
aged 4 years and 8 years will be monitored according to this 
surveillance case definition.
The estimated ASD prevalence in sites that reviewed both 
education and health care records was 60%–80% higher than 
the estimated ASD prevalence among sites that reviewed 
only health care records. Although ASD prevalence varied 
even among sites that reviewed education records, the total 
prevalence among these sites (15.9, 17.4, and 19.3 per 
1,000 children aged 4 years, respectively, for 2010–2014) is 
likely a more sensitive estimate of ASD prevalence among 
children aged 4 years, suggesting that the overall estimated 
ASD prevalence in the Early ADDM Network would have 
been higher had all sites had access to education records. 
Early intervention records also are an important source of 
information, particularly for tracking the age at earliest 
evaluation. For example, the percentage of children evaluated 
* In Arizona in 2012, the prevalence among children aged 4 years and children aged 8 years was significantly different (p<0.05 for chi-square test). In Missouri, the 
prevalence was significantly different in all 3 years. (In New Jersey, no differences were significant in any years.)
FIGURE 2. Trends in autism spectrum disorder prevalence* among children aged 4 years and 8 years — Early Autism and Developmental 
Disabilities Monitoring Network, three sites, United States, 2010, 2012, and 2014
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by age 36 months in Wisconsin was higher when early 
intervention records were included for 2014 but not for earlier 
years. Together, these findings suggest that early intervention 
and public education systems are a critical community resource 
for the evaluation of preschool-aged children who exhibit 
social, communication, and behavioral impairments. Lack of 
access to early intervention and education records, combined 
with indications from earlier reports (10–15) that many 
children with ASD are not evaluated until after age 4 years, 
suggests that the estimate of ASD prevalence among children 
aged 4 years might be an underestimate of the actual ASD 
prevalence in this birth cohort.
Other Studies of ASD Prevalence
Population-based data on the prevalence of ASD in 
preschool-aged children are limited, and various case 
ascertainment methods have been used; nevertheless, studies 
indicate that the prevalence of ASD in this age group has been 
higher in recent years. In 1996, estimated ASD prevalence 
among children aged 4 years in MADDSP was 3.1 per 1,000 
(95% CI: 2.6–3.7), and the estimated prevalence per 1,000 
children aged 8 years was 4.7 (95% CI: 4.0–5.5) (16). A 
study using similar methods conducted in Brick Township, 
New Jersey, reported an estimated ASD prevalence of 7.8 
per 1,000 children aged 3–5 years (95% CI: 5.1–11.3) in 
1998 (30). A study from South Carolina in 2006 using 
MADDSP methods found an ASD prevalence of 8.0 per 1,000 
children aged 4 years (31). A population-based study in the 
United Kingdom during 1998–1999 that used a multistage 
screening and diagnosis methodology to identify children 
with PDD reported a prevalence estimate of 6.3 per 1,000 
children aged 3.5–6.5 years (32). Another study using the same 
methods that was conducted several years later in a subsequent 
birth cohort reported a prevalence estimate of 5.9 per 1,000 
children aged 4–6 years (33). Approximately 10 years later, a 
report from the 2007 National Survey of Children’s Health 
(NSCH) described estimated ASD prevalence by parent or 
caregiver report to be 8.5 per 1,000 children aged 3–5 years 
(95% CI: 6.0–12.0), compared with 13.2 per 1,000 children 
aged 6–8 years (95% CI: 9.6–18.3) (6,34). Most recently, the 
2016 NSCH reported ASD prevalence estimates of 19.7 per 
1,000 children aged 3–5 years, 26.1 per 1,000 children aged 
6–11 years, and 26.5 per 1,000 children aged 12–17 years 
(9). The most recent data from the National Health Interview 
Survey showed a prevalence estimate (based on parent or 
caregiver report) of 22.3 per 1,000 children aged 3–7 years in 
2016, which was lower than the prevalence estimate among 
children aged 8–12 years (28.8) (34).
In addition to the findings among preschool-aged children, 
studies using different surveillance methods also have identified 
higher ASD prevalence among children in recent years 
(5–15,35). Several studies highlight changes in community 
practice for recognizing and diagnosing ASD in children with 
developmental concerns, as well as expansion of the diagnostic 
criteria for ASD during 1987–2013 to include children with 
fewer or more mild symptoms, as factors contributing to the 
higher prevalence (36–39). Although assessing whether ASD 
prevalence trends are, in part, associated with changes in 
etiologic risk is not possible with ADDM Network data, the 
heterogeneity of Early ADDM Network prevalence estimates 
across study sites, even among sites that reviewed both 
education and health care records, supports the hypothesis 
that differences in evaluation, diagnostic, and service practices 
affect measured prevalence. Previous data from the ADDM 
Network indicate a lower proportion of children with ASD 
with co-occurring intellectual disabilities (10–15) over time, 
consistent with improvements in the identification of children 
who have milder ASD. In addition, changes in the availability 
of services for children with ASD through insurance mandates 
(40), willingness of parents and providers to consider an ASD 
diagnosis, and greater awareness of and concern regarding ASD 
might contribute to the higher prevalence.
Early Identification of and 
Intervention for ASD
The American Academy of Pediatrics prioritized the early 
identification of ASD through its recommendation for 
universal ASD screening during pediatric preventive care visits 
at ages 18 and 24 months (22) and by the U.S. Department 
of Health and Human Services through the Healthy People 
2020 goal to increase the proportion of children with ASD who 
receive their first evaluation by age 36 months. Evidence linking 
early treatment for ASD with improved outcomes (18–21,41) 
implies that an absence or a delay in ASD identification could 
delay interventions and initiation of special services. Identifying 
the need for special services before school entry to minimize 
educational disruption and optimize educational outcomes 
might be especially important. 
In this report, across all sites and surveillance years, the 
median age at first known ASD evaluation among children 
aged 4 years with ASD ranged from 23 to 37 months, and 
48.8% to 88.9% received their first ASD evaluation by age 
36 months. The percentage of children with an ASD diagnosis 
varied widely by study site, ranging from 43.0% to 86.5%, with 
sites that reviewed only health care records generally reporting 
a greater percentage of children with an ASD diagnosis. This 
is not unexpected because other sites include children based 
Surveillance Summaries
12 MMWR / April 12, 2019 / Vol. 68 / No. 2 US Department of Health and Human Services/Centers for Disease Control and Prevention
wholly or partly on review of education records, which might 
not contain a formal ASD diagnosis. Among sites with data 
from all surveillance years and consistent data sources, the age 
at first evaluation was stable from 2010 to 2014 in Arizona and 
Missouri. In New Jersey, the age at first evaluation increased 
from 2010 to 2014. The Wisconsin site gained access to records 
from early intervention services for children aged <3 years 
for the 2014 surveillance year, which likely contributed to 
detecting a greater number of children with a first evaluation 
by age 36 months. Age at first evaluation might be easier 
to lower than age at diagnosis because diagnosing ASD in 
young children is challenging, which might be related to the 
prodromal nature of autism’s phenotypic onset that has recently 
become apparent through longitudinal studies of infant siblings 
at high risk for autism (42). However, greater awareness of 
ASD might result in more children being identified, including 
those with symptoms that do not fully manifest until the 
child is close to school age, increasing prevalence while also 
increasing the age of identification. Prevalence was higher 
among children aged 8 years than among those aged 4 years in 
some sites, which might reflect the identification of children 
with milder symptoms later in development or on school entry; 
this is supported by the difference in frequency of co-occurring 
intellectual disabilities between children aged 4 and 8 years. 
Efforts to identify developmental concerns as early as possible 
and decrease the age at first evaluation for all children with ASD 
are warranted. As recommended by the American Academy 
of Pediatrics, universal screening might identify children 
who need a comprehensive evaluation for ASD, even in the 
absence of previous developmental concerns or co-occurring 
intellectual disabilities, and improved tools for discerning the 
signs of ASD among the range of typical childhood behaviors 
might aid efforts to identify children earlier. Public health 
campaigns such as Learn the Signs. Act Early. (https://www.
cdc.gov/ncbddd/actearly/index.html) provide informational 
materials for parents, providers, and community members 
aimed at improving awareness of developmental milestones 
and increasing early identification of developmental delays so 
that children can receive appropriate services and treatments 
as early as possible.
No significant trends were found in the percentage of 
children with a documented ASD diagnosis or in the age at 
earliest known diagnosis. Children with an early evaluation 
can begin to receive behavioral and developmental services 
and interventions even if a formal ASD diagnosis is not made 
at that time. However, a formal diagnosis might be necessary 
to receive certain ASD services; therefore, the 35%–40% of 
children who met the ASD surveillance case definition but did 
not have a documented ASD diagnosis might not be eligible 
for services that depend on an ASD diagnosis.
Limitations
This report is subject to several limitations. First, because 
these ASD prevalence estimates are based on a record review, 
with no clinical examination, Early ADDM Network data 
reflect the information available in the source records. The 
amount and quality of the data determine the potential for 
a child to meet the ASD surveillance case definition and the 
extent to which they can be used to describe the characteristics 
of the identified population. Some children with ASD might 
not have been included because their records were incomplete 
or not available or they had not come to the attention of 
schools or clinical providers, which might have resulted in an 
underestimate of the ASD prevalence. Second, the types of 
source records varied across surveillance sites, and the lack of 
availability of education or early intervention records at some 
sites might have led to an underestimate of ASD prevalence 
among children aged 4 years in those sites and consequently for 
the Early ADDM Network overall. Third, early diagnoses of 
ASD might change if another diagnosis is determined to better 
account for a child’s signs and symptoms (6,43,44), potentially 
affecting the specificity of records-based surveillance. However, 
the ADDM Network clinician review process allows clinicians 
to change the ASD surveillance case status, even if the child 
has a previous ASD diagnosis, which helps decrease potential 
overestimates. Fourth, the availability of early intervention 
records in Wisconsin for 2014 but not for earlier years 
prevented the interpretation of changes in prevalence as well the 
age at earliest developmental evaluation and ASD diagnosis for 
that site. Fifth, measurement of intellectual ability in preschool-
aged children is less reliable than measurement among school-
aged children (26,27), preventing more specific classification 
of intellectual ability among children with ASD other than 
the presence or absence of intellectual disability. Sixth, data on 
intellectual ability were not available for all children, and the 
distribution of intellectual ability among the children with these 
data might not be generalizable to all children with ASD in the 
Early ADDM Network if the data on intellectual ability are not 
randomly missing. For example, children without a cognitive 
test score might not have been tested because their intellectual 
ability was clearly in the average to above-average range, thus 
overestimating the proportion of children with ASD and 
co-occurring intellectual disabilities. Seventh, the surveillance 
sites were selected through a competitive process and were not 
selected to be representative of children aged 4 years either in 
the United States or in the entire state in which surveillance 
occurred. Therefore, the estimated prevalence of ASD is limited 
to the surveillance areas. Finally, analyses of trends were limited 
to three sites with data and consistent data sources for all 3 
surveillance years, and within sites, data were sparse for certain 
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race/ethnicity groups. In addition, patterns of ASD prevalence 
and characteristics varied by site; therefore, in some cases, data 
could not be combined, limiting the statistical power.
Estimating ASD Prevalence Using 
Surveillance Data 
Surveillance data from the Early ADDM Network provides 
1) population-based ascertainment of ASD using multiple 
community data sources, including education and early 
intervention records for some sites; 2) inclusion of children 
with documentation of behaviors consistent with ASD but 
without a documented ASD diagnosis; 3) data on intellectual 
disability based on standardized tests of intellectual ability; and 
4) collection of information on the age at first comprehensive 
evaluation and ASD diagnosis, when present, that provide 
information on early identification of children with ASD. The 
record review method allows population-based estimates of ASD 
prevalence to be generated cost-effectively. Obtaining data from 
multiple community sources helps to improve the sensitivity of 
the surveillance system; education and early intervention records 
provide important information on services and early identification 
of children with ASD. The inclusion of children without a 
documented ASD diagnosis allows the surveillance system to 
identify children who might have less access to the health care 
system, such as children who receive evaluation services only in 
school where a formal ASD diagnosis might not be provided. 
Although the estimates are not representative of the United States 
or the state where each site was located, surveillance conducted 
in smaller areas close to evaluation and diagnostic centers might 
provide a more valid prevalence estimate than for larger areas where 
services might be lacking. Finally, the validity of the surveillance 
system compared with clinical examination of children has been 
assessed among children aged 8 years in a study using MADDSP 
data, which concluded that the ADDM method was unlikely 
to overestimate ASD prevalence, although some cases might be 
missed that would be identified an in-person evaluation using 
gold standard diagnostic instruments (45).
Conclusion
ASD surveillance among children aged 4 years provides 
information on progress made toward early identification goals 
and informs providers, particularly public schools, of upcoming 
service needs. ASD prevalence was stable in some sites participating 
in the Early ADDM Network and was higher in 2014 than 
2010 in one site; the higher prevalence might reflect improved 
identification of children with ASD by community providers. 
Lack of access to education records in some sites might have 
limited the sensitivity of records-based surveillance in those 
sites. However, variations in prevalence did not always align 
with access to data sources, and differences in evaluation and 
diagnostic services among different areas might account for some 
differences in findings across surveillance sites. This suggests that 
opportunities for improvements in services might exist based on 
successful programs implemented in specific areas. Continuing 
improvements in providing developmental evaluations to children 
as soon as developmental concerns are identified might result 
in earlier ASD diagnoses and earlier receipt of services, which 
might improve developmental outcomes. No treatment for ASD 
is available, although interventions might maximize each child’s 
ability to function and participate in the community (18–21,41).
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Appendix
Detailed Method for Estimating Surveillance Area Population Size of Partial Counties
For 2010, the number of children aged 4 years by sex and race/ethnicity was obtained for each census tract in the county from 
the 2010 decennial census counts. Next, each census tract was matched to the school district or districts to which it was fully or 
partially allocated, using the MABLE/Geocorr12: Geographic Correspondence Engine provided by the Missouri Census Data 
Center (http://mcdc.missouri.edu). A list of excluded or partially excluded census tracts was compiled, and the number of 
children aged 4 years living in these census tracts was subtracted from the overall and sex- and race-specific total numbers of 
children in the county. For census tracts that were partially allocated to a school district, weighting was based on the 2010 census 
population of the county. Finally, population counts of children aged 4 years in each specific census race/ethnicity category (white, 
black, American Indian/Alaska Native, Asian/Pacific Islander, other race/ethnicity, multiracial, and Hispanic) were adjusted to 
the distribution of the National Center on Health Statistics (NCHS) bridged-race category counts for the county, thereby 
incorporating children categorized in the census counts as multiracial or other race into the bridged-race categories reported by 
NCHS (white, black, Hispanic, American Indian/Alaska Native, and Asian/Pacific Islander). The same methods were used to 
estimate the prevalence of ASD among children aged 8 years living in the Early ADDM Network surveillance area.
For the nondecennial census years 2012 and 2014, denominators for sites that covered less than a full county were estimated by 
using school enrollment counts for the appropriate grades in the covered area and applying the distribution of these counts to the 
county-level bridged-race postcensal population estimates from NCHS (http://www.cdc.gov/nchs).
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TABLE 1. Prevalence* of autism spectrum disorder among children 
aged 4 years — Autism and Developmental Disabilities Monitoring 
Network, seven sites, United States, 2010, 2012, and 2014
Year, record source, 
and site
No. with 
ASD
Total 
population Prevalence (95% CI)
2010
Health care and education
Arizona† 123 9,265 13.3 (11.0–15.8)
New Jersey§,¶ 352 17,860 19.7 (17.7–21.9)
Utah¶,** 132 10,944 12.1 (10.1–14.3)
Total 607 38,069 15.9 (14.7–17.3)
Health care only
Missouri†† 103 12,095 8.5 (7.0–10.3)
Wisconsin§§ 73 8,303 8.8 (6.9–11.1)
Total 176 20,398 8.6 (7.4–10.0)
Combined total 783 58,467 13.4 (12.5–14.4)
2012
Health care and education
Arizona 128 9,621 13.3 (11.1–15.8)
New Jersey¶ 403 18,223 22.1 (20.0–24.4)
Utah¶ 152 11,398 13.3 (11.3–15.6)
Total 683 39,242 17.4 (16.1–18.8)
Health care only
Missouri 96 11,878 8.1 (6.5–9.9)
Wisconsin 128 8,336 15.4 (12.8–18.3)
Total 224 20,214 11.1 (9.7–12.6)
Combined total 907 59,456 15.3 (14.3–16.3)
2014
Health care and education
Arizona 130 9,624 13.5 (11.3–16.0)
Colorado¶¶ 113 8,438 13.4 (11.0–16.1)
New Jersey¶ 514 18,112 28.4 (26.0–30.9)
North Carolina¶,*** 231 14,893 15.5 (13.6–17.6)
Total 988 51,067 19.3 (18.2–20.6)
Health care only
Missouri 112 11,613 9.6 (7.9–11.6)
Wisconsin¶ 108 8,207 13.2 (10.8–15.9)
Total 220 19,820 11.1 (9.7–12.7)
Combined total 1,208 70,887 17.0 (16.1–18.0)
Abbreviations: ASD = autism spectrum disorder; CI = confidence interval.
 * Prevalence per 1,000 children aged 4 years living in the surveillance areas 
according to the 2010 decennial bridged-race population estimates 
(US Census Bureau. Census summary file 1: Tables PCT12H–PCT12O. 
Washington, DC: US Census Bureau; 2010), the vintage 2014 postcensal 
bridged-race population estimates for 2012 (http://www.cdc.gov/nchs), and 
the vintage 2016 postcensal bridged-race population estimates for 2014 
(http://www.cdc.gov/nchs).
 † Part of one county in metropolitan Phoenix for 2010, 2012, and 2014.
 § Essex and Union counties for 2010, 2012, and 2014.
 ¶ Site also reviewed records from early intervention sources.
 ** Tooele County, part of Salt Lake County, for 2010 and 2012 only.
 †† One county in metropolitan St. Louis for 2010, 2012, and 2014.
 §§ Dane and Rock counties for 2010, 2012, and 2014.
 ¶¶ One county in metropolitan Denver for 2014 only.
 *** Alamance, Chatham, Guilford, Orange, and Forsyth counties for 2014 only.
TABLE 2. Prevalence* of autism spectrum disorder among children 
aged 4 years, by sex — Early Autism and Developmental Disabilities 
Monitoring Network, seven sites, United States, 2010, 2012, and 2014
Year, 
record source, 
and site
Sex
Prevalence ratio, 
male to female  
(95% CI)†
Male Female
Prevalence 
(95% CI)
Prevalence 
(95% CI)
2010
Health care and education
Arizona 18.9 (15.2–23.3) 7.3 (5.0–10.3) 2.6 (1.7–3.9)
New Jersey§ 31.7 (28.1–35.5) 7.2 (5.5–9.2) 4.4 (3.3–5.8)
Utah§ 17.9 (14.6–21.7) 5.9 (4.0–8.3) 3.1 (2.0–4.6)
Health care only
Missouri 12.2 (9.6–15.3) 4.6 (3.0–6.7) 2.7 (1.7–4.1)
Wisconsin 12.5 (9.4–16.4) 4.8 (2.9–7.4) 2.6 (1.6–4.4)
2012
Health care and education
Arizona 21.3 (17.5–25.8) 4.6 (2.8–7.0) 4.7 (2.9–7.5)
New Jersey§ 33.6 (30.0–37.5) 9.9 (8.0–12.2) 3.4 (2.7–4.3)
Utah§ 20.7 (17.2–24.8) 5.7 (3.9–8.1) 3.6 (2.5–5.4)
Health care only
Missouri 12.9 (10.2–16.2) 3.2 (1.9–5.0) 4.0 (2.4–6.7)
Wisconsin 23.7 (19.4–28.8) 6.4 (4.2–9.4) 3.7 (2.4–5.7)
2014
Health care and education
Arizona 21.3 (17.4–25.8) 5.2 (3.3–7.7) 4.1 (2.7–6.4)
Colorado 22.3 (18.1–27.3) 4.3 (2.5–6.8) 5.2 (3.1–8.6)
New Jersey§ 44.0 (39.9–48.5) 12.1 (10.0–14.7) 3.6 (2.9–4.5)
North 
Carolina§
24.7 (21.3–28.5) 5.8 (4.2–7.8) 4.2 (3.0–5.9)
Health care only
Missouri 14.2 (11.3–17.5) 4.8 (3.2–7.0) 3.0 (1.9–4.6)
Wisconsin§ 20.8 (16.7–25.6) 4.8 (2.9–7.6) 4.3 (2.6–7.1)
Abbreviations: CI = confidence interval; PR = prevalence ratio.
* Prevalence per 1,000 children age 4 years living in the surveillance areas 
according to the 2010 decennial bridged-race population estimates (US Census 
Bureau. Census summary file 1: Tables PCT12H–PCT12O. Washington, DC: 
US Census Bureau; 2010), the vintage 2014 postcensal bridged-race population 
estimates for 2012 (http://www.cdc.gov/nchs), and the vintage 2016 postcensal 
bridged-race population estimates for 2014 (http://www.cdc.gov/nchs).
† Results for PRs considered statistically significant when the CI excludes the 
null value (PR = 1.0).
§ Site also reviewed records from early intervention sources.
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TABLE 3. Prevalence* of autism spectrum disorder among children aged 4 years, by race/ethnicity — Early Autism and Developmental Disabilities 
Monitoring Network, seven sites, United States, 2010, 2012, and 2014
Year, record source, and site
Prevalence (95% CI) Prevalence ratio (95% CI)†
White, non-Hispanic Black, non-Hispanic Hispanic White to black White to Hispanic 
2010 
Health care and education
Arizona 15.7 (12.4–19.7) —¶ 9.1 (6.2–12.9) — 1.7 (1.1–2.6)
New Jersey§ 18.9 (15.5–22.7) 16.7 (13.6–20.4) 22.5 (18.6–27.0) 1.1 (0.9–1.5) 0.8 (0.6–1.1)
Utah§ 14.0 (11.3–17.2) — 9.8 (6.7–13.8) — 1.4 (1.0–2.1)
Health care only
Missouri 9.3 (7.2–11.9) 3.8 (2.1–6.4) 14.4 (6.2–28.4) 2.5 (1.4–4.4) 0.6 (0.3–1.4)
Wisconsin 8.2 (6.0–10.9) — — — —
2012
Health care and education
Arizona 14.5 (11.4–18.1) 20.7 (8.3–42.7) 9.9 (6.8–13.8) 0.7 (0.3–1.5) 1.5 (1.0–2.2)
New Jersey§ 24.2 (20.3–28.5) 19.3 (15.9–23.1) 22.3 (18.6–26.6) 1.3 (1.0–1.6) 1.1 (0.8–1.4)
Utah§ 14.3 (11.5–17.5) — 11.3 (8.1–15.4) — 1.3 (0.9–1.8)
Health care only
Missouri 8.3 (6.3–10.8) 7.6 (5.1–11.0) — 1.1 (0.7–1.7) —
Wisconsin 13.9 (11.0–17.2) 7.6 (3.0–15.6) 15.6 (9.1–24.9) 1.8 (0.8–4.0) 0.9 (0.5–1.5)
2014
Health care and education
Arizona 15.2 (12.0–18.8) 14.9 (4.8–34.8) 11.1 (7.8–15.4) 1.0 (0.4–2.5) 1.4 (0.9–2.0)
Colorado 11.7 (8.3–16.2) 18.0 (10.5–28.9) 12.3 (9.1–16.2) 0.7 (0.4–1.2) 1.0 (0.6–1.5)
New Jersey§ 29.3 (24.8–34.2) 24.7 (20.9–29.0) 28.2 (24.1–32.8) 1.2 (0.9–1.5) 1.0 (0.8–1.3)
North Carolina§ 14.6 (11.8–17.8) 16.8 (13.2–21.0) 10.9 (7.5–15.3) 0.9 (0.6–1.2) 1.3 (0.9–2.0)
Health care only
Missouri 7.7 (5.8–10.1) 10.4 (7.3–14.3) — 0.7 (0.5–1.1) —
Wisconsin§ 13.1 (10.3–16.3) 9.7 (4.2–19.1) 11.5 (5.9–20.0) 1.3 (0.6–2.8) 1.1 (0.6–2.1)
Abbreviations: CI = confidence interval; PR = prevalence ratio.
* Prevalence per 1,000 children aged 4 years living in the surveillance areas according to the 2010 decennial bridged-race population estimates (US Census Bureau. 
Census summary file 1: Tables PCT12H–PCT12O. Washington, DC: US Census Bureau; 2010), the vintage 2014 postcensal bridged-race population estimates for 2012 
(http://www.cdc.gov/nchs), and the vintage 2016 postcensal bridged-race population estimates for 2014 (http://www.cdc.gov/nchs).
† Results for PRs considered statistically significant when the CI excludes the null value (PR = 1.0).
§ Site also reviewed records from early intervention sources.
¶ Estimates suppressed due to small cell sizes (N<5).
TABLE 4. Number and percentage of children with co-occurring intellectual disability* among children aged 4 years with autism spectrum disorder, 
by site, sex, and year — Early Autism and Developmental Disabilities Monitoring Network, four sites,† United States, 2010, 2012, and 2014
Site and 
sex
2010 2012 2014 2010–2014
Children 
with cognitive 
test scores
Children 
with co-occurring 
intellectual disability
Children 
with cognitive 
test scores
Children 
with co-occurring 
intellectual disability
Children 
with cognitive 
test scores
Children 
with co-occurring 
intellectual disability
p value§
No.  
(% of children 
with ASD) No. (%)
No.  
(% of children 
with ASD) No. (%)
No.  
(% of children 
with ASD) No. (%)
Site
Arizona 105 (85.4) 43 (41.0) 80 (62.5) 33 (41.3) 90 (69.2) 45 (50.0) 0.21
New Jersey 291 (82.7) 143 (49.1) 337 (83.6) 149 (44.2) 418 (81.3) 189 (45.2) 0.34
North 
Carolina
—¶ — — — 142 (61.5) 64 (45.1) —
Utah 97 (73.5) 40 (41.2) — — — — —
Sex**
Male 312 (82.3) 152 (48.7) 334 (79.1) 146 (43.7) 409 (79.9) 191 (46.7) 0.65
Female 84 (87.5) 34 (40.5) 83 (76.1) 36 (43.4) 99 (75.0) 43 (43.4) 0.69
Total** 396 (83.4) 186 (47.0) 417 (78.5) 182 (43.6) 508 (78.9) 234 (46.1) 0.84
Abbreviation: ASD = autism spectrum disorder.
 * Defined as a score of ≤70 on the most recent standardized cognitive ability test.
 † Including sites for which at least 60% of children with ASD had cognitive ability test score data for at least 1 surveillance year.
 § Cochran-Armitage trend test for percentage with intellectual disability; p<0.05 indicates statistical significance.
 ¶ No or insufficient data for site and surveillance year.
 ** Data restricted to sites with information for all 3 years (Arizona and New Jersey).
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TABLE 5. Median age at earliest known comprehensive evaluation and percentage of children evaluated by age 36 months among children 
aged 4 years with autism spectrum disorder — Early Autism and Developmental Disabilities Monitoring Network, seven sites, United States, 
2010, 2012, and 2014
Site and 
record source
2010 2012 2014
p value* 
Median age 
(months)
Total no. 
with ASD
No. (%) with 
evaluation 
by 36 months
Median age 
(months)
Total no. 
with ASD
No. (%) with 
evaluation 
by 36 months
Median age 
(months)
Total no. 
with ASD
No. (%) with 
evaluation 
by 36 months
Health care and education
Arizona 34.0 95 58 (61.1) 32.0 110 74 (67.3) 32.5 110 76 (69.1) 0.23
Colorado —† —† —† —† —† —† 34.0 93 75 (80.6) —§
New Jersey 26.0 307 235 (76.5) 29.0 344 271 (78.8) 34.0 403 269 (66.7) 0.002
North Carolina —† —† —† —† —† —† 23.0 198 164 (82.8) —§
Utah 32.0 107 75 (70.1) 32.0 115 72 (62.6) —† —† —† —§
Health care only
Missouri 30.0 88 61 (69.3) 37.0 80 39 (48.8) 29.0 90 67 (74.4) 0.46
Wisconsin 27.5 58 40 (69.0) 29.0 109 80 (73.4) 24.0 90 80 (88.9) —¶
Abbreviation: ASD = autism spectrum disorder.
* Cochran-Armitage trend test for proportion with evaluation by age 36 months; p<0.05 indicates statistical significance.
† No data for site and surveillance year.
§ Trend not estimated for sites with <3 years of data.
¶ Trend not estimated because records were included from early intervention sources for 2014 but not earlier years.
TABLE 6. Number and percentage of children aged 4 years with a previous autism spectrum disorder diagnosis and median age at earliest 
known diagnosis — Early Autism and Developmental Disabilities Monitoring Network, seven sites, United States, 2010, 2012, and 2014
Site and 
record source
2010 2012 2014 2010–2014
Total no. 
with ASD
No. (%) 
with any  
ASD  
diagnosis
Median age 
(months) 
of earliest 
known  
ASD 
diagnosis
Total no. 
with ASD
No. (%)  
with any  
ASD 
diagnosis
Median age 
(months) 
of earliest 
known  
ASD  
diagnosis
Total no. 
with ASD
No. (%) 
with any  
ASD  
diagnosis
Median age 
(months) 
of earliest 
known  
ASD 
diagnosis p value* 
Health care and education
Arizona 123 53 (43.1) 35.0 128 55 (43.0) 36.0 130 56 (43.1) 36.0 1.0
Colorado —† —† —† —† —† —† 113 72 (63.7) 31.0 —§
New Jersey 352 207 (58.8) 32.5 403 236 (58.6) 35.0 514 292 (56.8) 33.5 0.54
North Carolina —† —† —† —† —† —† 231 107 (46.3) 28.0 —§
Utah 132 106 (80.3) 35.0 152 122 (80.3) 35.0 —† —† —† —§
Health care only
Missouri 103 84 (81.6) 34.0 96 83 (86.5) 39.0 112 96 (85.7) 36.0 0.41
Wisconsin 73 61 (83.6) 34.0 128 93 (72.7) 39.0 108 77 (71.3) 33.0 —¶
Abbreviation: ASD = autism spectrum disorder.
* Cochran-Armitage trend test for percentage with any ASD diagnosis; p<0.05 indicates statistical significance.
† No data for site for surveillance year.
§ Trend not estimated for sites with <3 years of data.
¶ Trend not estimated because records were included from early intervention sources for 2014 but not earlier years.
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TABLE 7. Number and prevalence* of children aged 4 years meeting DSM-IV-TR or DSM-5 autism spectrum disorder case definition — Autism 
and Developmental Disabilities Monitoring Network, seven sites, United States, 2014
Site and record source
DSM-IV-TR DSM-5
Prevalence ratio (95% CI),† 
DSM-IV-TR to DSM-5No. Prevalence (95% CI) No. Prevalence (95% CI)
Health care and education
Arizona 130 13.5 (11.3–16.0) 102 10.6 (8.6–12.9) 1.3 (1.0–1.7)
Colorado 113 13.4 (11.0–16.1) 93 11.0 (8.9–13.5) 1.2 (0.9–1.6)
New Jersey§ 514 28.4 (26.0–30.9) 406 22.4 (20.3–24.7) 1.3 (1.1–1.4)
North Carolina§ 231 15.5 (13.6–17.6) 204 13.7 (11.9–15.7) 1.1 (0.9–1.4)
Health care only
Missouri 112 9.6 (7.9–11.6) 105 9.0 (7.4–10.9) 1.1 (0.8–1.4)
Wisconsin§ 108 13.2 (10.8–15.9) 93 11.3 (9.1–13.9) 1.2 (0.9–1.5)
Total 1,208 17.0 (16.1–18.0) 1,003 14.1 (13.3–15.1) 1.2 (1.1–1.3)
Abbreviations: CI = confidence interval; DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision; DSM-5 = Diagnostic and Statistical 
Manual of Mental Disorder, Fifth Edition.
* Prevalence per 1,000 children aged 4 years living in the surveillance areas according to the vintage 2016 postcensal bridged-race population estimates for 2014 
(http://www.cdc.gov/nchs).
† Results for PRs considered statistically significant when the CI excludes the null value (PR = 1.0).
§ Site also reviewed records from early intervention sources.
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